Let us not conflate burn risk and race onto patients with atopic dermatitis

In this issue of the Annals of Allergy, Asthma& Immunology, Alexis et al1 evaluated the efficacy and safety of abrocitinib by race, ethnicity, and Fitzpatrick skin types (FST). This analysis included pooled data from 945 patients older than 12 years who received abrocitinib 200 mg, abrocitinib 100 mg, or placebo from 3 double-blind placebo-controlled atopic dermatitis (AD) trials.1 Race and ethnicity were self-reported. Only data from White (n = 628), Asian (n = 204), and Black (n = 83) patients were analyzed because of low numbers of other racial subgroups, including multiracial patients and those who did not self-report race.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research